Stockscreener 앱 받기
2.86
4.34%
-0.1299
시간 외 거래:
2.86
전일 마감가:
$2.9899
열려 있는:
$2.95
하루 거래량:
35,395
Relative Volume:
1.19
시가총액:
$29.15M
수익:
-
순이익/손실:
$-23.87M
주가수익비율:
-0.1454
EPS:
-19.67
순현금흐름:
$-47.63M
1주 성능:
-11.73%
1개월 성능:
-5.92%
6개월 성능:
-20.78%
1년 성능:
-54.60%
1일 변동 폭
$2.76
$3.09
1주일 범위
$2.76
$3.475
52주 변동 폭
$2.37
$7.00
폴리피드 Stock (PYPD) Company Profile
PYPD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
2.86 | 29.15M | 0 | -23.87M | -47.63M | -19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
폴리피드 Stock (PYPD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2021-09-14 | 개시 | JMP Securities | Mkt Outperform |
| 2021-07-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-11-24 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | 개시 | Alliance Global Partners | Buy |
| 2020-07-21 | 개시 | BMO Capital Markets | Outperform |
| 2020-07-21 | 개시 | Barclays | Overweight |
| 2020-07-21 | 개시 | Raymond James | Outperform |
모두보기
폴리피드 주식(PYPD)의 최신 뉴스
PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Head-To-Head Contrast: PolyPid (NASDAQ:PYPD) versus OraSure Technologies (NASDAQ:OSUR) - Defense World
Surgical Outcomes Pioneer PolyPid Takes Center Stage at Major Healthcare Conference - StockTitan
PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire Inc.
PolyPid (NASDAQ:PYPD) Stock Rating Upgraded by RODMAN&RENSHAW - Defense World
PolyPid to Report Fourth Quarter and Full-Year 2024 - GlobeNewswire
Major Surgical Innovation Updates Expected: PolyPid Sets Critical Q4 Earnings Date - StockTitan
Rodman & Renshaw sets PolyPid stock at Buy with $13 target - MSN
PolyPid Regains Nasdaq Compliance with Private Placement Boost - TipRanks
Surgical Site Infections Pipeline 2024: Key Companies, MOA, - openPR
Critical Survey: InfuSystem (NYSE:INFU) vs. PolyPid (NASDAQ:PYPD) - Defense World
Earnings call transcript: PolyPid Q3 2024 focuses on trial progress By Investing.com - Investing.com Australia
Earnings call transcript: PolyPid Q3 2024 focuses on trial progress - Investing.com India
PolyPid Ltd. announced that it expects to receive $14.470133 million in funding - Marketscreener.com
FY2024 Earnings Forecast for PolyPid Issued By HC Wainwright - Defense World
PolyPid (NASDAQ:PYPD) Price Target Lowered to $11.00 at HC Wainwright - Defense World
PolyPid Advances Phase 3 Trial and Secures Financing - TipRanks
PolyPid stock poised for 2026 launch despite adjusted target from H.C. Wainwright - Investing.com Australia
PolyPid stock poised for 2026 launch despite adjusted target from H.C. Wainwright By Investing.com - Investing.com South Africa
PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million - The Manila Times
PolyPid's Surgical Infection Drug Trial Advances with $14.5M Funding Boost; Phase 3 Results Due Q2 2025 - StockTitan
FY2024 Earnings Estimate for PolyPid Issued By HC Wainwright - Defense World
PolyPid (NASDAQ:PYPD) Given “Buy” Rating at HC Wainwright - Defense World
Critical Survey: PAVmed (NASDAQ:PAVM) and PolyPid (NASDAQ:PYPD) - Defense World
PolyPid announces collaboration with ImmunoGenesis in solid tumors - The Cancer Letter
PolyPid announces research, development collaboration with ImmunoGenesis - Yahoo Finance
PolyPid enters R&D pact with ImmunoGenesis By Investing.com - Investing.com South Africa
PolyPid stock hits 52-week low at $2.81 amid market challenges - Investing.com
PolyPid enters R&D pact with ImmunoGenesis - Investing.com India
PolyPid Collaborates with ImmunoGenesis to Boost Cancer Immunotherapy - TipRanks
PolyPid Announces Research and Development Collaboration - GlobeNewswire
PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy - Yahoo Finance
PolyPid Ltd. Announces Research and Development Collaboration with ImmunoGenesis, Inc. Leveraging PLEX Technology to Enhance Cancer Immunotherapy - Marketscreener.com
PolyPid stock touches 52-week low at $2.93 amid market challenges - Investing.com Nigeria
PolyPid Faces Nasdaq Non-Compliance Challenge - TipRanks
PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance - GlobeNewswire
PolyPid Faces Nasdaq Non-Compliance, Pivotal Trial Results Due December | PYPD Stock News - StockTitan
PolyPid Ltd. (NASDAQ:PYPD) Q3 2024 Earnings Call Transcript - Insider Monkey
PolyPid Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
PolyPid Ltd (PYPD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
PolyPid Reports Q3 Results Amid SHIELD II Trial Progress - TipRanks
PolyPid Announces SHIELD II Trial Progress and Financials - TipRanks
PolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire
폴리피드 (PYPD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.95%
2.39%
자본화:
|
볼륨(24시간):